Updated: March 5, 2021
Oxford University said on Friday that a clinical trial has shown that a vaccine it developed with Astrazeneca PLC worked against a more transmissible variant of the coronavirus first identified in the United Kingdom.
The efficacy of the vaccine against the UK variant of the coronavirus was 75 percent, compared with 84 percent for older variants.
[read_more id="2" more="Read full article" less="Read less"]
The UK, South African and Brazilian variants of the coronavirus are now in the United States and elsewhere in the world, and there have been questions about whether the vaccine will work against them as well.